Perceptive Capital Solutions Corp · NASDAQ:PCSC
Perceptive Capital Solutions — SPAC Merger (July 2026)
17 slides from Perceptive Capital Solutions's SPAC merger presentation, Jul 9, 2026
Slide 1: SimpleScreen v2 sPMA Top-Line Readout
July 9th, 2026 SimpleScreen v2 sPMA Top-Line Readout
Slide 2: Disclaimer: Forward Looking Statements
Disclaimer Forward Looking Statements Certain statements included in this Presentation that are not historical facts are forward-looking statements. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect
Slide 3: Disclaimer (Cont'd)
Disclaimer (Cont’d) If any of these risks materialize or PCSC’s or Freenome’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither PCSC nor Freenome presently know or that PCSC and
Slide 4: SimpleScreen CRC v2 met all primary and secondary endpoints
Endpoint CRC v1 (US Census adjusted) CRC v2 (US Census adjusted) N Value (95% CI) N Value (95% CI)I Pass (Yes/No) Sensitivity for CRC (Primary) 72 81.1% (71.3%, 88.1%) 89 80.4%, (70.2%, 87.7%) Yes Sensitivity for Advanced Precancerous Lesions (APL) (Primary) 2567 13.7% (12.4%, 15.0%) 1570 18.2%, (16
Slide 5: SimpleScreen CRC v2 improved APL/HGD detection while maintaining CRC sensitivity in line with v1
SimpleScreen CRC v2 improved APL/HGD detection while maintaining CRC sensitivity in line with v1 v2 detects more invasive Stage I T2 lesions, while detecting fewer Stage I T1 lesions (interpretability limited due to small sample size). US Census adjusted sensitivity by lesion category and CRC stage
Slide 6: Performance improvements with SimpleScreen CRC v2 across all APL subtypes
Performance improvements with SimpleScreen CRC v2 across all APL subtypes Advanced Precancerous Lesion (APL) Subtypes Subcategory Label Definition HGD/CIS APL 2.1 Adenoma with high-grade dysplasia (HGD) or carcinoma in situ (CIS), any size Villous / tubulovillous APL 2.2 Adenoma, villous growth patt
Slide 7: SimpleScreen CRC v2 reduces modeled CRC cases and deaths while increasing life-years gained
SimpleScreen CRC v2 reduces modeled CRC cases and deaths while increasing life-years gained per 100,000 people screened CRC cases CRC deaths Life-years gained Projected lifetime impact per 100K adults screened from ages 45 to 75 using the COSMOS-CRC model 1 Key Health Economic Model Inputs: Screenin
Slide 8: Relative projected impact of APL sensitivity, adherence, and CRC sensitivity on health outcomes
Relative projected impact of APL sensitivity, adherence, and CRC sensitivity on health outcomes Projected Lifetime Impact per 100K Screened CRC Cases (Fewer) CRC Deaths (Fewer) Life-Years Gained 1% Increase in APL Sensitivity -91 -32 +342 1% Increase in Adherence -39 -18 +206 1% Increase in CRC Sens
Slide 9: Freenome Company Roadmap
Freenome Company Roadmap
Slide 10: Multiple value-driving catalysts on the horizon in CRC, lung, and PCD
Multiple value-driving catalysts on the horizon in CRC, lung, and personalized cancer detection (PCD)* Early Access Program (EAP); Analytical/Clinical Validation (AV/CV): United States Preventive Services Task Force (USPSTF); Laboratory Developed Test (LDT); In Vitro Diagnostic (IVD) Anticipated Mil
Slide 11: Freenome Appendix
Freenome Appendix
Slide 12: Test Versioning Programs
Test Versioning Programs Final v2 Design DNA Extraction ✓ NGS Conversion ✓ NGS Platform (Library Prep, Multiplex, Capture, Sequencing) ✓ Process/reagent variability reduction (Mitigate degradation) ✓ Computational ✓ Assay Analytical Performance ~3x cfDNA molecule recovery compared to v1 Analytical P
Slide 13: Modeled CRC v2 sensitivity when standardized to external study case mixes
When standardized to external study case mixes, modeled CRC v2 sensitivity is 83% to 85% and APL remains near 18% Table below shows the estimated performance when considering the stage and APL subtype proportions from other blood-based CRC screening studies PREEMPT included a higher proportion of ea
Slide 14: CRC and APL Sensitivity: Observed and US Census Adjusted Performance
CRC and APL Sensitivity: Observed and US Census (IUP) Adjusted Performance Table 09.02.01.01.EC CRC-V2 as Index Test Evaluable Cohort (EC N=9001) Evaluation Endpoint Observed Fraction Observed Value (95% CI)I US Census Weighted Fraction US Census Weighted Value (95% CI)I Pass (Yes/No) CRC-V2 Primary
Slide 15: High-Grade Dysplasia Sensitivity: Observed and US Census Adjusted Performance
High-Grade Dysplasia Sensitivity: Observed and US Census (IUP) Adjusted Performance Table 09.02.02.01.HGD for CRC-V2 as Index Test HGD Set (HGD N=157) Evaluation Endpoint Observed Fraction Observed Value (95% CI)I US Census Weighted Fraction US Census Weighted Value (95% CI)I Pass (Yes/No) CRC-V2 Se
Slide 16: Specificity: Observed and US Census Adjusted Performance
Specificity: Observed and US Census (IUP) Adjusted Performance Table 09.03.01.01.EC Diagnostic Accuracy: Other Diagnostic Performance for CRC-V2 as Index Test Evaluable Cohort (EC N=9,001) Evaluation Endpoint Observed Fraction Observed Value (95% CI)I US Census Weighted Value (95% CI)I CRC-V2 Specif
Slide 17: Additional Information about the Proposed Business Combination and Where to Find It
Additional Information about the Proposed Business Combination and Where to Find It As previously disclosed, Perceptive Capital Solutions Corp. (“PCSC”), Freenome Holdings, Inc. (“Freenome”), StarNet Merger Sub I, Corp., a Delaware corporation and a wholly-owned subsidiary of PCSC, and StarNet Merge
Perceptive Capital Solutions — SPAC Merger (July 2026) on 6ix